Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders | Zendy

Andrea Calcagno | Zendy; Ivano Dal Conte | Zendy; Dario Cattaneo | Zendy; Roberto Testi | Zendy; Massimiliano Mistrangelo | Zendy; Cristina Gervasoni | Zendy; Amedeo De Nicolò | Zendy; Stefano Bonora | Zendy; Antonio D’Avolio | Zendy; Giovanni Di Perri | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders

Author(s) -

Andrea Calcagno,

Ivano Dal Conte,

Dario Cattaneo,

Roberto Testi,

Massimiliano Mistrangelo,

Cristina Gervasoni,

Amedeo De Nicolò,

Stefano Bonora,

Antonio D’Avolio,

Giovanni Di Perri

Publication year - 2020

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01902-20

Subject(s) - medicine , tenofovir , emtricitabine , pre exposure prophylaxis , gastroenterology , diarrhea , gastrointestinal disease , human immunodeficiency virus (hiv) , disease , viral load , antiretroviral therapy , immunology , men who have sex with men , syphilis

Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research